Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document the U.S. disclosure record for its Helus Pharma clinical-stage pharmaceutical business. Form 6-K reports furnished by the Canadian issuer attach company news releases and, when specified, incorporate exhibits by reference into Form F-10 shelf registration materials.
The filings cover the company’s novel serotonergic agonist pipeline, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as well as clinical-research collaborations, regulatory-policy statements, scientific advisory board changes, management appointments, chief executive transition disclosures, listing and operating-name updates, and capital-structure matters related to shelf and equity distribution activity.
Cybin Inc. is filing a Form F-10 under the multijurisdictional disclosure system to register up to $1,700,000,000 of securities under an amended short form base shelf prospectus, increased from $800,000,000. The shelf covers common shares, warrants, units, debt securities and subscription receipts, which may be offered over a 25‑month period, and also permits secondary sales by selling securityholders. A corresponding U.S. registration statement covers an equivalent of about US$1.23 billion.
The amendment explains that part of the capacity is earmarked to qualify warrant exercises and resale of previously issued shares, and notes a recent registered direct offering and repayment of US$22.8 million of convertible debentures, leaving no loans and borrowings outstanding. Cybin reports cash of about US$202 million as of December 19, 2025 and expects this to fund operations for the next 12 months, including planned spending on its CYB003, CYB004 and CYB005 mental‑health programs, while acknowledging ongoing negative operating cash flow and the likelihood of needing additional capital over time.
Cybin Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The filing mainly serves a technical purpose by stating that Exhibit 99.1 from this report is incorporated by reference into Cybin’s existing Form F-10 registration statement, allowing that exhibit to be treated as part of the registration materials.
Cybin Inc. (CYBN): Schedule 13G/A Amendment No. 2 filed by Point72 entities reporting beneficial ownership of Cybin common shares. The filing lists 6,410,778 Common Shares beneficially owned with shared voting and dispositive power and 0 under sole power, representing 9.9% of the class as of the close of business on November 13, 2025.
The reported amount includes 2,109,338 Common Shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership blocker; some warrants are not presently exercisable due to this cap. As context, the aggregate percentage as of September 30, 2025 was based on 25,188,217 Common Shares outstanding as of September 16, 2025. The filing also notes that as of September 30, 2025, the reporting person may have been deemed to beneficially own 1,239,629 Common Shares, or 4.9%.
Ownership is held through Point72 Associates, LLC under an investment management agreement; Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen are reporting persons. They certify the securities were not acquired to change or influence control.
Cybin Inc. furnished a Form 6-K for November 2025, making available interim consolidated financial statements and the related MD&A for the three and six months ended September 30, 2025. The filing also includes CEO and CFO certifications and a news release dated November 13, 2025.
Exhibits 99.1 and 99.2 are incorporated by reference into Cybin’s Registration Statement on Form F-10 (File No. 333-289139). Cybin reports annually on Form 40-F.
Cybin Inc. (CYBN): Venrock-affiliated entities and individuals filed a Schedule 13G reporting beneficial ownership of 5,111,412 common shares, representing 9.99% of the class as of the 10/31/2025 event date.
The stake comprises common shares plus pre-funded warrants and common warrants, all subject to a 9.99% Beneficial Ownership Blocker. The percentage is based on 27,616,381 common shares outstanding as of 10/28/2025, 22,277,750 shares issued in a registered direct offering that closed on 10/31/2025, and 1,271,162 shares issuable upon warrant exercise. Cover-page percentages are rounded down to 9.9% due to EDGAR limits.
The reporting group includes Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, L.L.C., Venrock Healthcare Capital Partners EG, L.P., their managers, and individuals Nimish Shah and Bong Y. Koh. They certified the holdings were not acquired to change or influence control.